Robert E. Hoffman's most recent trade in FibroBiologics Inc was a trade of 22,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| FibroBiologics Inc | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Esperion Therapeutics Inc. | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 7,040 | 7,040 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 5,280 | 5,280 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| TuHURA Biosciences Inc. | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 51,275 | 51,275 | - | - | Options (Right to Buy) | |
| FibroBiologics Inc | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2024 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| TuHURA Biosciences Inc. | Robert E. Hoffman | Director, President, CEO, and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 59,800 | 68,902 (0%) | 0% | 0 | Common Stock, par value $0.001 per share | |
| TuHURA Biosciences Inc. | Robert E. Hoffman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 1,200,634 | 1,200,634 | - | - | Option (right to buy) | |
| TuHURA Biosciences Inc. | Robert E. Hoffman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 400,145 | 455,145 (3%) | 3% | 0 | Common Stock | |
| TuHURA Biosciences Inc. | Robert E. Hoffman | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.47 per share. | 15 Feb 2022 | 55,000 | 55,000 (0%) | 0% | 0.5 | 25,795 | Common Stock |
| TuHURA Biosciences Inc. | Robert E. Hoffman | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2021 | 3,519,170 | 3,519,170 | - | - | Options (Right to Buy) | |
| TuHURA Biosciences Inc. | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 100,000 | 100,000 | - | - | Options (Right to Buy) | |
| Kura Oncology Inc | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 23,000 | 23,000 | - | - | Option to purchase common stock | |
| TuHURA Biosciences Inc. | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2020 | 120,000 | 120,000 | - | - | Options (Right to Buy) |